(Q37364829)

19 August 2017

1 reference

title

L-dopa therapy for Parkinson's disease: past, present, and future (English)

1 reference

19 August 2017

1 reference

Toshiharu Nagatsua

1

1 reference

PubMed ID

19131039

19 August 2017

Makoto Sawadab

series ordinal

2

1 reference

PubMed ID

19131039

19 August 2017

language of work or name

1 reference

1 January 2009

1 reference

Parkinsonism and Related Disorders

19 August 2017

1 reference

19 August 2017

15 Suppl 1

1 reference

19 August 2017

S3-8

1 reference

Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Precursors of adrenal epinephrine and norepinephrine in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Norepinephrine synthesis from tyrosine-C-14 in isolated perfused guinea pig heart

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

On the presence of 3-hydroxytyramine in brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Distribution of catechol compounds in human brain

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Excretion of dopamine in diseases of basal ganglia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Modification of Parkinsonism--chronic treatment with L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

The metabolism of orally administered l-DOPA in Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

O-Methylation of Epinephrine and Other Catechols in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

The metabolism of L-3-0-methyldopa, aprecursor of dopa in man

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Dopaminergic neurons intrinsic to the striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Localization of L-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

1 reference

7 January 2021

Levodopa: is toxicity a myth?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Levodopa--toxic or neuroprotective?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

The therapeutic potential of monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Selegiline slows the progression of the symptoms of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic L-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Current status of gene therapy trials for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970004-5

7 January 2021

10.1016/S1353-8020(09)70004-5

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

19131039